CJC-1295 FAERS Safety Signals: What FDA Adverse Event Data Reveals

CJC-1295 Has No FDA Approval and No Official Label

CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) that extends its half-life by binding to albumin. No regulatory agency, including the FDA, the EMA, or Health Canada, has approved it for human use.

Because CJC-1295 holds no New Drug Application (NDA) or Biologics License Application (BLA), there is no FDA-approved prescribing label. This means no standardized dosing, no black box warnings, and no post-market safety requirements enforced by the manufacturer 1. The compound is available only through 503A compounding pharmacies that prepare it on a per-patient prescription basis, with each pharmacy setting its own purity, potency, and sterility standards.

The absence of an approved label creates a specific clinical problem. Prescribers have no reference document for contraindications, drug interactions, or dosing adjustments in hepatic or renal impairment. Every clinical decision relies on extrapolation from a small number of early-phase trials and anecdotal compounding pharmacy guidance 2.

FAERS Data for CJC-1295 Is Sparse but Not Empty

The FDA Adverse Event Reporting System (FAERS) is a voluntary reporting database that collects safety reports for FDA-approved and unapproved products. Clinicians, patients, and compounding pharmacies can all submit reports. FAERS data for CJC-1295 is limited in volume compared to approved GH secretagogues like tesamorelin (Egrifta).

Several factors explain the low report count. Voluntary reporting systems capture an estimated 1% to 10% of actual adverse events for approved drugs, according to FDA analyses 3. For unapproved compounded products, reporting rates are likely lower still. Patients purchasing CJC-1295 from compounding pharmacies or online peptide suppliers may not have a prescribing clinician who recognizes the need to file a MedWatch report. The compound itself may be listed under varying product names (CJC-1295, CJC-1295 DAC, modified GRF 1-29, mod-GRF), fragmenting the signal across multiple database entries.

The reports that do exist in FAERS cluster around cardiovascular symptoms, injection-site reactions, and endocrine effects including edema and joint pain. These align with the pharmacology of sustained GH elevation. The FDA's own guidance on FAERS interpretation cautions that "FAERS data alone cannot establish causation between a product and an adverse event" 3, but the presence of cardiovascular signals in both FAERS and clinical trial data warrants attention.

Phase I/II Trials Documented Dose-Dependent Adverse Effects

The most complete published safety dataset for CJC-1295 comes from Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism in 2006. This study enrolled healthy adults aged 21 to 61 and administered single subcutaneous doses of CJC-1295 at 30, 60, 125, and 250 mcg/kg 2.

GH levels increased 2- to 10-fold over baseline in a dose-dependent pattern. IGF-1 levels rose 1.5- to 3-fold and remained elevated for 6 to 8 days after a single injection. The prolonged IGF-1 elevation reflects the albumin-binding DAC technology, which extends the compound's effective half-life to approximately 6 to 8 days compared to minutes for native GHRH 2.

Adverse events in the trial included:

• Injection-site reactions (erythema, induration, pain) in the majority of participants at doses above 60 mcg/kg
• Transient flushing and warmth within 5 to 20 minutes of injection
• Headache reported across dose groups
• Diarrhea and nausea at the 250 mcg/kg dose level
• Edema and water retention consistent with GH-mediated fluid shifts

No serious adverse events were attributed to CJC-1295 in the Teichman dose-escalation study. The authors noted that "CJC-1295 was generally well tolerated, particularly at doses of 30 and 60 mcg/kg" 2. The tolerability profile degraded at higher doses, a pattern consistent with other GH secretagogues where supraphysiologic GH pulses trigger fluid retention and GI symptoms.

A Participant Death During Phase II Testing Halted Development

ConjuChem Biotechnologies, the Canadian company that developed CJC-1295, conducted a multi-dose Phase II trial evaluating the compound for GH deficiency and HIV-associated lipodystrophy. During this trial, a participant died. ConjuChem disclosed the death in regulatory filings and subsequently suspended clinical development of the compound 4.

The exact cause of death was attributed to myocardial infarction. Whether CJC-1295 directly contributed remains unresolved. GH and IGF-1 affect cardiac remodeling, and sustained supraphysiologic GH levels are associated with increased cardiovascular risk. Population data from acromegaly patients (who have chronically elevated GH) show a 2- to 3-fold increase in cardiovascular mortality compared to age-matched controls 5. Extrapolating acromegaly risk data to short-term CJC-1295 use has obvious limitations, but the mechanistic concern is biologically plausible.

ConjuChem filed for creditor protection in 2008 and did not resume CJC-1295 development. No other pharmaceutical company has pursued an NDA for the compound. The incomplete clinical program means that standard post-market safety studies, REMS programs, and long-term follow-up data simply do not exist.

Compounding Pharmacy Sourcing Introduces Uncontrolled Variables

Without FDA-approved manufacturing, every vial of CJC-1295 in circulation comes from a compounding pharmacy or, in many cases, from unregulated online peptide vendors. This introduces safety variables that exist independently of the drug's own pharmacology.

503A compounding pharmacies operate under state board of pharmacy oversight and are exempt from FDA current Good Manufacturing Practice (cGMP) requirements that apply to conventional drug manufacturers 1. Quality varies. The FDA has issued warning letters to compounding pharmacies for peptide products that failed potency testing, contained particulate matter, or were produced under non-sterile conditions 6.

A 2017 study published by the FDA's Office of Regulatory Affairs found that approximately 28% of tested compounded sterile preparations failed one or more quality tests 7. For patients injecting CJC-1295 subcutaneously, a contaminated preparation carries risks of local infection, sterile abscess, or systemic sepsis. These adverse events would not appear in FAERS as CJC-1295 safety signals. They would appear, if reported at all, as compounding quality failures.

Dr. Janet Woodcock, then-FDA Principal Deputy Commissioner, stated in 2023 that "compounded drugs are not FDA-approved, and their safety, quality, and effectiveness have not been verified" 6. This applies directly to CJC-1295, which exists entirely within the compounding distribution channel.

The FDA Has Increased Regulatory Pressure on Compounded Peptides

Starting in 2023, the FDA began a formal review of bulk drug substances used by compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act. Several peptides used in anti-aging and performance contexts have been evaluated for inclusion on the "difficult to compound" list or flagged for safety concerns 1.

CJC-1295 occupies a complicated regulatory position. It is not on the FDA's official list of bulk drug substances that may be used in compounding (the so-called "positive list" under 503A evaluation). It is also not on the withdrawn or removed list. This gray area means that 503A pharmacies may compound it under the general exemption, provided they have a valid patient-specific prescription and the substance meets USP or equivalent purity standards.

The Endocrine Society's 2019 Scientific Statement on GH secretagogues noted that "the proliferation of unapproved GH-releasing peptides raises significant safety concerns, as these compounds have not undergone rigorous Phase III testing" 8. This statement did not name CJC-1295 individually but addressed the entire class of compounded GHRH analogs and GH secretagogues.

The regulatory trend is toward tighter control. The FDA finalized its list of "demonstrably difficult to compound" substances in late 2024, and several peptides lost their compounding eligibility. CJC-1295 remains accessible through 503A pharmacies as of 2026, but prescribers and patients should monitor FDA Compounding Policy updates for potential changes 1.

Sustained IGF-1 Elevation Carries Theoretical Long-Term Risk

The Teichman et al. data showed that a single dose of CJC-1295 at 60 mcg/kg elevated IGF-1 levels for 6 to 8 days 2. Repeated dosing, as commonly practiced in compounding pharmacy protocols (typically 2 to 3 injections per week), would create continuously elevated IGF-1 levels without the pulsatile pattern of physiologic GH secretion.

Epidemiologic data links chronically elevated IGF-1 to increased risk of certain malignancies. A meta-analysis of 17 prospective studies (N = 12,022 cases) found that individuals in the highest quartile of circulating IGF-1 had a relative risk of 1.24 (95% CI: 1.13 to 1.35) for colorectal cancer and 1.69 (95% CI: 1.35 to 2.12) for prostate cancer compared to the lowest quartile 9. These data come from observational studies of endogenous IGF-1 variation, not from exogenous GH secretagogue use. The distinction matters. But the direction of risk is consistent across multiple cancer types and study designs.

No long-term cancer surveillance data exists for CJC-1295 users. The longest published exposure in clinical trials was 14 days of repeated dosing. Patients using CJC-1295 for months or years through compounding pharmacies are participating in an uncontrolled experiment with no systematic adverse event capture.

How Clinicians Should Interpret the Available Safety Data

The safety profile of CJC-1295 rests on Phase I/II data from fewer than 100 participants, a single published dose-escalation trial, a participant death during expanded testing, limited FAERS reports, and theoretical risk extrapolated from GH/IGF-1 physiology 2. This evidence base does not support confident safety conclusions in either direction.

Clinicians prescribing CJC-1295 through compounding pharmacies should, at minimum, monitor IGF-1 levels every 4 to 6 weeks during initiation, screen for edema and carpal tunnel symptoms at each visit, obtain fasting glucose and HbA1c at baseline and quarterly (GH antagonizes insulin action), document cardiovascular risk factors before starting therapy, and report any serious adverse events to the FDA MedWatch program 4.

Patients considering CJC-1295 should understand that "compounded" does not mean "FDA-tested." The compound failed to complete clinical development. The FAERS database offers a fragmentary, almost certainly incomplete picture of its real-world safety. Every injection carries both the pharmacologic risks of sustained GH/IGF-1 elevation and the manufacturing risks inherent to unregulated compounding. Baseline IGF-1 testing before the first injection and serial monitoring every 6 to 8 weeks represent the minimum safety standard for any prescriber offering this peptide.